[Clinical experience using solco trichovac in the treatment of trichomonad infections in women].
A lactobacillus vaccine was administered to 102 women with vaginal trichomonad infections. In about half of these patients a local trichomonacidal treatment using Nitroimidazol derivatives was also carried out. After completion of the primary course of treatment 84% of the women were free of symptoms and no trichomonads could be demonstrated; within one year this figure had risen to 96%. Reinfections after completion of the primary course of treatment and after booster vaccination occurred in only 4-5% of the cases. The bacterial status of the vagina as described by Jirovec and Peter improved markedly, the degree of improvement being related to the number of vaccine treatments performed. After only one vaccination an improvement from Grace V (= trichomoniasis) to Grade I or II was seen in 64% of the patients. Six months after the primary course of treatment the vaginal status of 82% of the women was rated Grade I or II, and six months after the booster vaccination given after one year the corresponding figure was 80%. The lactobacillus vaccine treatment described represents a promising development in the therapy of trichomonad and bacterial infections in women.
D000328:Adult; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007779:Lactobacillus acidophilus / Q000276:immunology*; D008722:Methods; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D012008:Recurrence; D014247:Trichomonas Vaginitis / Q000188:drug therapy / Q000628:therapy*
D001428:Bacterial Vaccines; D008795:Metronidazole
Klinische Erfahrungen mit solco trichovac bei der Behandlung der Trichomonaden-Infektion der Frau.